methyl 4-bromoisoquinoline-7-carboxylate | 2007916-56-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: methyl 4-bromoisoquinoline-7-carboxylate
• 英文别名: Methyl 4-bromoisoquinoline-7-carboxylate
• CAS: 2007916-56-3
• 化学式: C₁₁H₈BrNO₂
• 分子量: 266.094
• InChiKey: NKPFPFQGYSIGMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-bromoisoquinoline-7-carboxylate 在 sodium azide 、 copper(ll) sulfate pentahydrate 、 sodium carbonate 、 sodium ascorbate 、 L-脯氨酸 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 以90%的产率得到methyl 4-aminoisoquinoline-7-carboxylate
  参考文献：
  名称：

  Hit-to-lead optimization of a latency-associated nuclear antigen inhibitor against Kaposi’s sarcoma-associated herpesvirus infections

  摘要：

  The Latency-associated nuclear antigen (LANA) plays a central role for the latent persistence of the Kaposi's Sarcoma Herpesvirus (KSHV) in the human host and helps to establish lifelong infections. Herein, we report our efforts towards hit-to-lead generation starting from a previously discovered LANADNA inhibitor. By tethering the viral genome to the host nucleosomes, LANA ensures the segregation and persistence of the viral DNA during mitosis. LANA is also required for the replication of the latent viral episome during the S phase of the cell cycle. We aim to inhibit the interaction between LANA and the viral genome to prevent the latent persistence of KSHV in the host organism. Medicinal chemistry-driven optimization studies and structure-activity-relationship investigation led to the discovery of an improved LANA inhibitor. The functional activity of our compounds was evaluated using a fluorescence polarization (FP)-based interaction inhibition assay and electrophoretic mobility shift assay (EMSA). Even though a crystal structure of the ligand protein complex was not available, we successfully conducted hit optimization toward a low micromolar protein-nucleic acid-interaction inhibitor. Additionally, we applied STD-NMR studies to corroborate target binding and to gain insights into the binding orientation of our most potent inhibitor, providing opportunities for further rational design of more efficient LANAtargeting anti KSHV agents in future studies. (C) 2020 The Author(s). Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112525
• 作为产物：
  描述：

  7-溴异喹啉 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-溴代丁二酰亚胺(NBS) 、 溶剂黄146 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 80.0~100.0 ℃ 、310.27 kPa 条件下， 反应 17.0h， 生成 methyl 4-bromoisoquinoline-7-carboxylate
  参考文献：
  名称：

  [EN] BICYCLIC COMPOUNDS
  [FR] COMPOSÉS BICYCLIQUES

  摘要：

  本文提供了包含所述化合物的药物组合物，用于治疗癌症。具体的癌症包括那些由YAP/TAZ介导或由YAP/TAZ与TEAD相互作用调节的癌症。

  公开号：

  WO2020214734A1

文献信息

• [EN] TEAD INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TEAD ET LEURS UTILISATIONS
  申请人：CEDILLA THERAPEUTICS INC

  公开号：WO2022204452A1

  公开（公告）日：2022-09-29

  The present application relates to compounds of formula (I'), pharmaceutically acceptable compositions thereof, and methods of using the same. The compounds of formula I' are TEAD inhibitors, useful in the treatment of cancer.

  本申请涉及式(I')的化合物，其药学上可接受的组合物以及使用它们的方法。式I'的化合物是TEAD抑制剂，在癌症治疗中有用。
• BICYCLIC COMPOUNDS
  申请人：Vivace Therapeutics, Inc.

  公开号：EP3956033A1

  公开（公告）日：2022-02-23
• [EN] BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2020214734A1

  公开（公告）日：2020-10-22

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

  本文提供了包含所述化合物的药物组合物，用于治疗癌症。具体的癌症包括那些由YAP/TAZ介导或由YAP/TAZ与TEAD相互作用调节的癌症。
• Hit-to-lead optimization of a latency-associated nuclear antigen inhibitor against Kaposi’s sarcoma-associated herpesvirus infections
  作者：Philine Kirsch、Saskia C. Stein、Aylin Berwanger、Julia Rinkes、Valentin Jakob、Thomas F. Schulz、Martin Empting

  DOI：10.1016/j.ejmech.2020.112525

  日期：2020.9

  The Latency-associated nuclear antigen (LANA) plays a central role for the latent persistence of the Kaposi's Sarcoma Herpesvirus (KSHV) in the human host and helps to establish lifelong infections. Herein, we report our efforts towards hit-to-lead generation starting from a previously discovered LANADNA inhibitor. By tethering the viral genome to the host nucleosomes, LANA ensures the segregation and persistence of the viral DNA during mitosis. LANA is also required for the replication of the latent viral episome during the S phase of the cell cycle. We aim to inhibit the interaction between LANA and the viral genome to prevent the latent persistence of KSHV in the host organism. Medicinal chemistry-driven optimization studies and structure-activity-relationship investigation led to the discovery of an improved LANA inhibitor. The functional activity of our compounds was evaluated using a fluorescence polarization (FP)-based interaction inhibition assay and electrophoretic mobility shift assay (EMSA). Even though a crystal structure of the ligand protein complex was not available, we successfully conducted hit optimization toward a low micromolar protein-nucleic acid-interaction inhibitor. Additionally, we applied STD-NMR studies to corroborate target binding and to gain insights into the binding orientation of our most potent inhibitor, providing opportunities for further rational design of more efficient LANAtargeting anti KSHV agents in future studies. (C) 2020 The Author(s). Published by Elsevier Masson SAS.